PAX5 and lymphoma: Additionally, several DLBCL cell lines and primary human DLBCLs harbor PAX5-TSS2 mutations (Extended Data Fig. 5d and Supplementary Table 4) and on average demonstrate increased ZCCHC7 mRNA levels relative to cell lines and tumors without such mutations (Extended Data Fig. 5e,f), suggesting that PAX5 promoter mutations might promote ZCCHC7 overexpression in lymphoma cells.